Pacira Pharmaceuticals (PCRX) PT Raised to $34 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Pacira Pharmaceuticals (PCRX) PT Raised to $37 at Leerink Partners
April 10, 2018 6:16 AM EDTLeerink Partners raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $37.00 (from $34.00) while maintaining a Market Perform rating.
... MorePacira Pharmaceuticals (PCRX) PT Raised to $80 at Wedbush After EXPAREL Nerve Block sNDA Approved
April 9, 2018 3:54 PM EDTWedbush raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $80.00 (from $72.00) while maintaining a Outperform rating after the FDA approved a new indication for EXPAREL (bupivacaine liposome injectable suspension) for use as an interscalene brachial plexus nerve block to relieve pain associated with... More
Pacira Pharmaceuticals (PCRX) PT Raised to $48 at H.C. Wainwright
April 9, 2018 7:14 AM EDTH.C. Wainwright raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $48.00 (from $45.00) while maintaining a Buy rating.
... MorePacira Pharma (PCRX) Reports FDA Approval of Supplemental New Drug Application for EXPAREL
April 9, 2018 5:41 AM EDTPacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) to broaden the use of EXPAREL® (bupivacaine liposome injectable suspension) to include administration via interscalene brachial plexus block to produce postsurgical regional analgesia. With this approval, EXPAREL is the first long-acting, single-dose nerve block available for patients undergoing upper extremity surgeries, such as total shoulder arthroplasty or rotator cuff repair.
Brachial plexus blocks are emerging as a... More
Pacira Pharmaceuticals (PCRX) PT Raised to $48 at Seaport Global Securities
April 9, 2018 1:14 AM EDTSeaport Global Securities raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $48.00 (from $42.00) while maintaining a Buy rating.
... MorePacira Pharmaceuticals (PCRX) PT Raised to $34 at Canaccord Genuity
April 9, 2018 1:10 AM EDTCanaccord Genuity raised its price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $34.00 (from $32.00) while maintaining a Hold rating.
... MoreFDA approves Pacira Pharma (PCRX) EXPAREL sNDA
April 6, 2018 1:09 PM EDTFDA approves Pacira Pharma (NASDAQ: PCRX) EXPAREL sNDA
... More